Business Wire

New pulp mill boosts Suzano's sales and revenue in the second quarter of 2025

Share

Suzano, the world’s largest pulp producer, announces its results for the second quarter of 2025 (2Q25), reporting sales of 3.7 million tonnes of pulp and paper. Sales increased 28% over the same period in 2024 (2Q24), mainly reflecting the strong operational contribution of the new Ribas do Rio Pardo pulp mill, whose production started in July 2024. Net revenue in the quarter totaled R$13.3 billion, a 16% increase compared to 2Q24.

The expansion of pulp production capacity in Brazil, combined with the positive contribution to paper sales from the mills recently acquired in the United States and favorable FX rates, mitigated the impact on net revenue of lower pulp prices in the global market compared to 2Q24. As a result, Suzano's adjusted EBITDA reached R$6.1 billion and operating cash generation totaled R$4.1 billion. Net profit totaled R$5.0 billion positively impacted by the accounting impact of US dollar denominated debt and hedging operations translating into Brazilian Real.

Beto Abreu, CEO of Suzano, commented:

“We have just marked the first year of our new pulp mill in Ribas do Rio Pardo, whose strong operational performance has already strengthened our cost competitiveness. At the same time, we continued to execute on our long-term strategy of value-accretive growth, announcing our landmark joint venture with Kimberly-Clark. We will remain disciplined and focused on capturing the potential economic gains we believe exist in the new joint venture and on further enhancing our competitiveness in the coming years.”

Suzano’s net leverage in U.S. dollars ended the quarter at 3.1 times. The cash cost of pulp production was R$832 per tonne (excluding downtime), a result that demonstrates the beginning of a downward trend in costs, which is expected to become even more significant in the second half of 2025.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250806382862/en/

Contacts

Hawthorn Advisors
Jamie Plotnek
suzano@hawthornadvisors.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

k-ID Strengthens Leadership Team with Former Xbox Family Product Lead Mike Mongeau1.9.2025 10:00:00 EEST | Press release

k-ID, the global compliance platform transforming age-appropriate digital experiences for young people worldwide, today announced the appointment of Mike Mongeau as Head of Product. Mongeau joins k-ID from Microsoft, where he spearheaded Xbox’s family gaming experience, ensuring millions of kids could game safely while giving parents the tools to feel confident about their play. Mongeau will leverage his extensive experience in youth safety technology and product development to advance k-ID's mission of creating trusted, age-appropriate digital experiences for kids and teens globally. His appointment comes as k-ID rapidly expands its partnerships with leading publishers and platforms, such as Discord, Hasbro, Nexus Mods, and GorillaTag. "Mike brings an invaluable combination of deep technical expertise in family safety and a genuine passion for empowering young people in digital spaces," said Kieran Donovan, CEO and Co-Founder of k-ID. "His track record at Xbox demonstrates exactly the

CapVest to Acquire Majority Stake in STADA from Bain Capital and Cinven1.9.2025 09:49:00 EEST | Press release

CapVest Partners LLP (“CapVest”), a leading global investment firm, has today signed a definitive agreement with Bain Capital and Cinven to acquire the majority stake in STADA Arzneimittel AG “(STADA” or “the Company”), a leading healthcare and pharmaceuticals company specializing in Consumer Healthcare, Generics and Specialty pharmaceuticals. Headquartered in Bad Vilbel, Germany, STADA is a leading European pharmaceutical company focused on three strategic pillars: Consumer Healthcare, Generics and Specialty Pharmaceuticals. The company was acquired by Bain Capital and Cinven in 2017. Working with management, the two international investment firms helped transform the company from a traditional German generics business into a leading, diversified global healthcare platform with a strategic focus on Consumer Healthcare, Generics and Specialty Pharmaceuticals. During this period, STADA grew into a multifaceted, resilient company, generating revenues in excess of €4 billion, delivering a

New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM31.8.2025 12:15:00 EEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results of new analyses from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. Data from the 12-month follow-up of the ongoing open-label extension (OLE) period of HELIOS-B were presented during an oral session at the European Society of Cardiology (ESC) Congress 2025 held in Madrid, Spain. These data reflect outcomes of treatment through up to 48 months, including the initial double-blind period of 33-36 months, and highlight the ongoing clinical benefit of vutrisiran, which causes rapid knockdown of the disease-causing transthyretin (TTR) protein, including a 37% risk reduction in the composite endpoint of all-cause mortality (ACM) or first cardiovascular (CV) event in the overall population (p<0.001) and a 42% risk reduction in th

WETEX Opens Broad Investment Horizons for International Companies31.8.2025 09:30:00 EEST | Press release

Under the directives of HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, and the patronage of HH Sheikh Ahmed bin Saeed Al Maktoum, Chairman of the Dubai Supreme Council of Energy, Dubai Electricity and Water Authority (DEWA) will organise the 27th edition of the Water, Energy, Technology and Environment Exhibition (WETEX) from 30 September to 2 October 2025 at the Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250830023664/en/ WETEX opens broad investment horizons for international companies (Photo: AETOSWire) WETEX embodies the UAE's pioneering position in clean and renewable energy and sustainability. It also supports Dubai's ambitious vision of a sustainable economy. The exhibition covers multiple areas including water, energy, smart cities, green mobility, artificial intelligence and digital transformation. “WETEX reflects the UAE's unwa

Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 19:00:00 EEST | Press release

Daiichi Sankyo Europe is pleased to announce the initiation of the development of new oral triple combination tablets in Europe of bempedoic acid, ezetimibe, and different doses of a statin (atorvastatin or rosuvastatin), with the potential to lower low-density lipoprotein cholesterol (LDL-C) levels.9 It is well known that combination therapies reduce the pill burden for patients, potentially enhancing treatment adherence and facilitating treatment with a goal of improving cardiovascular outcomes.9,10 “As bempedoic acid and ezetimibe are already approved as a single-dose therapy, the development of an oral triple combination tablet with different doses of a statin, can make it easier for physicians to tailor treatment to the individual needs of each patient,” says Dr. Stefan Seyfried, Vice President and Head Medical Affairs Specialty Medicines, Daiichi Sankyo Europe. “This approach exemplifies our dedication to our motto: ‘we care for every heartbeat’.” “The management of dyslipidaemia

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye